The three companies have jointly conducted clinical trials of antibody-coupled drugs to treat urethra skin cancer

recently, Seattle Genetics and Astellas announced a partnership agreement with Mercedon to jointly conduct clinical trials of the antibody conceding drug (ADC) Enfortumab Vedotin and Keytruda for the first-line treatment of locally advanced or metastatic urethra cancer.The three companies will fund the launch of a Global Registration Phase III study, led by Seattle Genetics, which is currently in communication with regulators about the design of the trial, which is expected to start in the first half of 2020.Enfortumab Vedotin has filed a listing application with the FDA for locally advanced or metastatic urethroid skin cancer with PD-1/L1 inhibitors and platinum-containing new assisted chemotherapy/assisted chemotherapy, and is currently undergoing FDA review with the PDUFA date of March 15 next year.Enfortumab vedotin uses Seattle Genetics' proprietary connectivity technology to connect the micro-tube destroyer MMAE to the anti-Netin-4 monoclonal antibody.Enfortumab vedotin targets the cell adhesion molecule Nectin-4, expressed on a variety of solid tumors. (Drug Information Network)